A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of Deucravacitinib versus placebo at
Week 24 and safety and tolerability of Deucravacitinib versus placebo in adults with Alopecia
Areata.